Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO EQUITY RATIO
N/A
Electra Therapeutics Inc.
Market Cap
$207.25M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.51M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$205.89M
Debt to Equity Ratio
0.03
TTM Avg
0.03
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$209.24M
Debt to Equity Ratio
0.21
TTM Avg
0.16
3Y Avg
0.18
5Y Avg
0.12
Market Cap
$203.91M
Debt to Equity Ratio
N/A
TTM Avg
0.99
3Y Avg
1.42
5Y Avg
1.17
Market Cap
$211.51M
Debt to Equity Ratio
0.13
TTM Avg
0.20
3Y Avg
0.12
5Y Avg
0.08
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $207.25M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $207.51M | 0.00 | 0.01 | 0.01 | 0.01 |
| Pro-Dex, Inc. (PDEX)vs › | $207.75M | 0.38 | 0.42 | 0.43 | 0.50 |
| Sionna Therapeutics, Inc. (SION)vs › | $205.89M | 0.03 | 0.03 | 0.01 | 0.01 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.24M | 0.21 | 0.16 | 0.18 | 0.12 |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $203.91M | N/A | 0.99 | 1.42 | 1.17 |
| Alector, Inc. (ALEC)vs › | $203.18M | N/A | 0.76 | 0.50 | 0.39 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.51M | 0.13 | 0.20 | 0.12 | 0.08 |
| Compugen Ltd. (CGEN)vs › | $211.80M | 0.03 | 0.04 | 0.03 | 0.03 |
| Exagen Inc. (XGN)vs › | $201.61M | 2.09 | 1.95 | 1.44 | 1.12 |
Debt/Equity
N/A
Current Ratio
N/A
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
